Prognostic Value of Ferritin in ASCT MM Patients: Integration with GEP Models and ISS Series Systems

Overview

Journal Blood Cancer J

Date 2024 Feb 14

PMID 38355688

Authors

Wancheng Guo

Yihao Zhan

David Mery

Eric R Siegel

Fumou Sun

Yan Cheng

Timothy Cody Ashby

Zijun Zhang

Clyde Bailey

Daisy V Alapat

Hongling Peng

Samer Al Hadidi

Sharmilan Thanendrarajan

Carolina Schinke

Maurizio Zangari

Frits van Rhee

Guido Tricot

John D Shaughnessy

Fenghuang Zhan

Affiliations

Soon will be listed here.

Citing Articles

Effect of tandem autologous stem cell transplantation on survival in pediatric patients with high-risk solid tumors in South China.

Luo Z, Fan L, Guo W, Yang J, Li Z, Huang Y World J Stem Cells. 2025; 17(2):100621.

PMID: 40061267 PMC: 11885945. DOI: 10.4252/wjsc.v17.i2.100621.

References

Greipp P, San Miguel J, Durie B, Crowley J, Barlogie B, Blade J . International staging system for multiple myeloma. J Clin Oncol. 2005; 23(15):3412-20. DOI: 10.1200/JCO.2005.04.242. View

Tricot G, Barlogie B, Jagannath S, Bracy D, Mattox S, Vesole D . Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood. 1995; 86(11):4250-6. View

Bataille R, Boccadoro M, Klein B, Durie B, Pileri A . C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood. 1992; 80(3):733-7. View

Merlini G, WALDENSTROM J, JAYAKAR S . A new improved clinical staging system for multiple myeloma based on analysis of 123 treated patients. Blood. 1980; 55(6):1011-9. View

Younes M, Hachfi H, Hammouda F, Younes K, Ben Hammouda S, Jguirim M . [Survival prognosis factors in multiple myeloma]. Tunis Med. 2015; 92(6):399-405. View

Durie B, Salmon S . A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975; 36(3):842-54. DOI: 10.1002/1097-0142(197509)36:3<842::aid-cncr2820360303>3.0.co;2-u. View

Cassuto J, Krebs B, Viot G, Dujardin P, MASSEYEFF R . beta 2 Microglobulin, a tumour marker of lymphoproliferative disorders. Lancet. 1978; 2(8080):108-9. DOI: 10.1016/s0140-6736(78)91428-9. View

Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst H, Goldschmidt H, Rosinol L . Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol. 2015; 33(26):2863-9. PMC: 4846284. DOI: 10.1200/JCO.2015.61.2267. View

Bataille R, Durie B, Grenier J, Sany J . Prognostic factors and staging in multiple myeloma: a reappraisal. J Clin Oncol. 1986; 4(1):80-7. DOI: 10.1200/JCO.1986.4.1.80. View

10.

Dewald G, Kyle R, Hicks G, Greipp P . The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood. 1985; 66(2):380-90. View

11.

DAgostino M, Cairns D, Lahuerta J, Wester R, Bertsch U, Waage A . Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project. J Clin Oncol. 2022; 40(29):3406-3418. DOI: 10.1200/JCO.21.02614. View

12.

Kiba T, Ito T, Nakashima T, Okikawa Y, Kido M, Kimura A . Bortezomib and dexamethasone for multiple myeloma: higher AST and LDH levels associated with a worse prognosis on overall survival. BMC Cancer. 2014; 14:462. PMC: 4078016. DOI: 10.1186/1471-2407-14-462. View

13.

Carbone P, Kellerhouse L, Gehan E . Plasmacytic myeloma. A study of the relationship of survival to various clinical manifestations and anomalous protein type in 112 patients. Am J Med. 1967; 42(6):937-48. DOI: 10.1016/0002-9343(67)90074-5. View

14.

. Prognostic features in the third MRC myelomatosis trial. Medical Research Council's Working Party on Leukaemia in Adults. Br J Cancer. 1980; 42(6):831-40. PMC: 2010574. DOI: 10.1038/bjc.1980.330. View

15.

Tricot G, Sawyer J, Jagannath S, Desikan K, Siegel D, Naucke S . Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. J Clin Oncol. 1997; 15(7):2659-66. DOI: 10.1200/JCO.1997.15.7.2659. View